Accelerated Resolution Therapy for Early Maladaptive Grief

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 7 words
  2. Re-verified, no change to tracked fieldsv10
  3. Study sites: 2 to 4v9
  4. Eligibility criteria shortened, about 14 wordsv8
  5. Collaborators expanded, about 5 wordsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary and study completion dates: Feb 2028 to Mar 14, 2028
    • Start date: Oct 23, 2023 to Nov 17, 2023
    v6
  2. Trial status: Not Yet Recruiting to Recruitingv5 Show 6 more changesShow less
    • Primary endpoints revised (3)
    • Enrollment target: 330 to 440
    • Study sites: 1 to 2
    • Start date changed from estimate of Oct 2023 to Oct 23, 2023
    • Eligibility criteria shortened, about 1 word
    • Study description expanded, about 1 word
  3. Start date: Jul 2023 to Oct 2023v4
  4. Primary and study completion dates: Nov 2023 to Feb 2028
    • Start date: Apr 2023 to Jul 2023
    v3
  5. Start date: Dec 2022 to Apr 2023
    • Study description revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mayo Clinic
1,027 trials monitored
See 130 trials at risk
The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.
Trial Details
NCT Number NCT05624879
Lead Sponsor Mayo Clinic
Collaborators: National Institute on Aging (NIA)
Conditions
(from sponsor)		 Grief
Enrollment 440 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov